异位抗血栓化合物激活和抑制蛋白二硫异构酶的机制基础

IF 5.5 2区 医学 Q1 HEMATOLOGY Journal of Thrombosis and Haemostasis Pub Date : 2024-10-23 DOI:10.1016/j.jtha.2024.09.036
Nathan Ponzar, Mathivanan Chinnaraj, Anna Pagotto, Vincenzo De Filippis, Robert Flaumenhaft, Nicola Pozzi
{"title":"异位抗血栓化合物激活和抑制蛋白二硫异构酶的机制基础","authors":"Nathan Ponzar, Mathivanan Chinnaraj, Anna Pagotto, Vincenzo De Filippis, Robert Flaumenhaft, Nicola Pozzi","doi":"10.1016/j.jtha.2024.09.036","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Protein Disulfide Isomerase (PDI) is a promising target for combating thrombosis. Extensive research over the past decade has identified numerous PDI-targeting compounds. However, limited information exists regarding how these compounds control PDI activity, which complicates further development.</p><p><strong>Objectives: </strong>To define the mechanism of action of two allosteric antithrombotic compounds of therapeutic interest, quercetin-3-O-rutinoside and bepristat-2a.</p><p><strong>Methods: </strong>A multi-pronged approach that integrates single-molecule spectroscopy, steady-state kinetics, single turnover kinetics, and site-specific mutagenesis.</p><p><strong>Results: </strong>PDI is a thiol-isomerase consisting of two catalytic a-domains and two inactive b-domains arranged in the order a-b-b'-a'. The active sites CGHC are located in the a and a' domains. The binding site of quercetin-3-O-rutinoside and bepristat-2a is in the b' domain. Using a library of nine FRET sensors, we show that quercetin-3-O-rutinoside and bepristat-2a globally alter PDI structure and dynamics, leading to ligand-specific modifications of its shape and reorientation of the active sites. Combined with enzyme kinetics and mutagenesis of the active sites, FRET data reveal that binding of quercetin-3-O-rutinoside results in a twisted enzyme with reduced affinity for the substrate. In contrast, bepristat-2a promotes a more compact conformation of PDI, in which a greater enzymatic activity is achieved by accelerating the nucleophilic step of the a domain, leading to faster formation of the covalent enzyme-substrate complex.</p><p><strong>Conclusions: </strong>This work reveals the mechanistic basis underlying PDI regulation by antithrombotic compounds quercetin-3-O-rutinoside and bepristat-2a, and points to novel strategies for furthering the development of PDI-targeting compounds into drugs.</p>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":5.5000,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Mechanistic basis of activation and inhibition of Protein Disulfide Isomerase by allosteric antithrombotic compounds.\",\"authors\":\"Nathan Ponzar, Mathivanan Chinnaraj, Anna Pagotto, Vincenzo De Filippis, Robert Flaumenhaft, Nicola Pozzi\",\"doi\":\"10.1016/j.jtha.2024.09.036\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Protein Disulfide Isomerase (PDI) is a promising target for combating thrombosis. Extensive research over the past decade has identified numerous PDI-targeting compounds. However, limited information exists regarding how these compounds control PDI activity, which complicates further development.</p><p><strong>Objectives: </strong>To define the mechanism of action of two allosteric antithrombotic compounds of therapeutic interest, quercetin-3-O-rutinoside and bepristat-2a.</p><p><strong>Methods: </strong>A multi-pronged approach that integrates single-molecule spectroscopy, steady-state kinetics, single turnover kinetics, and site-specific mutagenesis.</p><p><strong>Results: </strong>PDI is a thiol-isomerase consisting of two catalytic a-domains and two inactive b-domains arranged in the order a-b-b'-a'. The active sites CGHC are located in the a and a' domains. The binding site of quercetin-3-O-rutinoside and bepristat-2a is in the b' domain. Using a library of nine FRET sensors, we show that quercetin-3-O-rutinoside and bepristat-2a globally alter PDI structure and dynamics, leading to ligand-specific modifications of its shape and reorientation of the active sites. Combined with enzyme kinetics and mutagenesis of the active sites, FRET data reveal that binding of quercetin-3-O-rutinoside results in a twisted enzyme with reduced affinity for the substrate. In contrast, bepristat-2a promotes a more compact conformation of PDI, in which a greater enzymatic activity is achieved by accelerating the nucleophilic step of the a domain, leading to faster formation of the covalent enzyme-substrate complex.</p><p><strong>Conclusions: </strong>This work reveals the mechanistic basis underlying PDI regulation by antithrombotic compounds quercetin-3-O-rutinoside and bepristat-2a, and points to novel strategies for furthering the development of PDI-targeting compounds into drugs.</p>\",\"PeriodicalId\":17326,\"journal\":{\"name\":\"Journal of Thrombosis and Haemostasis\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.5000,\"publicationDate\":\"2024-10-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Thrombosis and Haemostasis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jtha.2024.09.036\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thrombosis and Haemostasis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jtha.2024.09.036","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:蛋白二硫异构酶(PDI)是一个很有希望的抗血栓靶点。过去十年的广泛研究发现了许多 PDI 靶向化合物。然而,关于这些化合物如何控制 PDI 活性的信息却很有限,这使得进一步开发变得复杂:明确两种具有治疗意义的异位抗血栓化合物--槲皮素-3-O-芸香糖苷和贝普利司他-2a--的作用机制:方法:采用多管齐下的方法,将单分子光谱学、稳态动力学、单一周转动力学和位点特异性诱变结合起来:PDI是一种硫醇异构酶,由两个催化a域和两个非活性b域组成,其排列顺序为a-b-b'-a'。活性位点 CGHC 位于 a 和 a'结构域中。槲皮素-3-O-芸香糖苷和贝普利司他-2a的结合位点位于b'结构域。利用九种 FRET 传感器库,我们发现槲皮素-3-O-芸香糖苷和贝普利司他-2a 会全面改变 PDI 的结构和动力学,导致配体特异性地改变其形状和活性位点的重新定向。结合酶动力学和活性位点的诱变,FRET 数据显示,与槲皮素-3-O-芸香糖苷结合会导致酶扭曲,对底物的亲和力降低。相比之下,贝普利司他-2a 能促进 PDI 形成更紧凑的构象,在这种构象中,通过加速 a 结构域的亲核步骤,使酶与底物的共价复合物更快地形成,从而获得更高的酶活性:这项研究揭示了抗血栓化合物槲皮素-3-O-芸香糖苷和贝普利司他-2a调控PDI的机理基础,并为进一步将PDI靶向化合物开发成药物指出了新的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Mechanistic basis of activation and inhibition of Protein Disulfide Isomerase by allosteric antithrombotic compounds.

Background: Protein Disulfide Isomerase (PDI) is a promising target for combating thrombosis. Extensive research over the past decade has identified numerous PDI-targeting compounds. However, limited information exists regarding how these compounds control PDI activity, which complicates further development.

Objectives: To define the mechanism of action of two allosteric antithrombotic compounds of therapeutic interest, quercetin-3-O-rutinoside and bepristat-2a.

Methods: A multi-pronged approach that integrates single-molecule spectroscopy, steady-state kinetics, single turnover kinetics, and site-specific mutagenesis.

Results: PDI is a thiol-isomerase consisting of two catalytic a-domains and two inactive b-domains arranged in the order a-b-b'-a'. The active sites CGHC are located in the a and a' domains. The binding site of quercetin-3-O-rutinoside and bepristat-2a is in the b' domain. Using a library of nine FRET sensors, we show that quercetin-3-O-rutinoside and bepristat-2a globally alter PDI structure and dynamics, leading to ligand-specific modifications of its shape and reorientation of the active sites. Combined with enzyme kinetics and mutagenesis of the active sites, FRET data reveal that binding of quercetin-3-O-rutinoside results in a twisted enzyme with reduced affinity for the substrate. In contrast, bepristat-2a promotes a more compact conformation of PDI, in which a greater enzymatic activity is achieved by accelerating the nucleophilic step of the a domain, leading to faster formation of the covalent enzyme-substrate complex.

Conclusions: This work reveals the mechanistic basis underlying PDI regulation by antithrombotic compounds quercetin-3-O-rutinoside and bepristat-2a, and points to novel strategies for furthering the development of PDI-targeting compounds into drugs.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis 医学-外周血管病
CiteScore
24.30
自引率
3.80%
发文量
321
审稿时长
1 months
期刊介绍: The Journal of Thrombosis and Haemostasis (JTH) serves as the official journal of the International Society on Thrombosis and Haemostasis. It is dedicated to advancing science related to thrombosis, bleeding disorders, and vascular biology through the dissemination and exchange of information and ideas within the global research community. Types of Publications: The journal publishes a variety of content, including: Original research reports State-of-the-art reviews Brief reports Case reports Invited commentaries on publications in the Journal Forum articles Correspondence Announcements Scope of Contributions: Editors invite contributions from both fundamental and clinical domains. These include: Basic manuscripts on blood coagulation and fibrinolysis Studies on proteins and reactions related to thrombosis and haemostasis Research on blood platelets and their interactions with other biological systems, such as the vessel wall, blood cells, and invading organisms Clinical manuscripts covering various topics including venous thrombosis, arterial disease, hemophilia, bleeding disorders, and platelet diseases Clinical manuscripts may encompass etiology, diagnostics, prognosis, prevention, and treatment strategies.
期刊最新文献
Validating International Classification of Diseases Code 10th Revision algorithms for accurate identification of pulmonary embolism. High risk of long-term recurrence after a first episode of venous thromboembolism during pregnancy or postpartum: the REcurrence after a PrEgnAncy related Thrombosis (REPEAT) Study. Validation of clinical risk assessment scores for venous thromboembolism in patients with cancer: a population-based cohort study. Déjà vu all over again: a recurrent flaw in anticoagulant study design. Intensive FVIII replacement in haemophilia patients with hypertrophic synovium: a randomized study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1